BIOMAT Database Logo BIOMAT Database Logo

[Chemotherapy with bevacizumab (BV)+modified FOLFOX6 for unresectable colorectal cancer]. 2009

Rikio Matsumoto, and Toru Kuroda, and Hirofumi Yamada, and Kumi Hasegawa, and Yutaka Mamiya, and Akira Kon
Department of Surgery, Sekishindo Hospital.

We examined efficacy and safety of bevacizumab (BV)+modified FOLFOX6 (mFOLFOX6) regimen for unresectable colorectal cancer. We had 16 patients: liver metastases 8, lung metastases 4, local recurrences 2, and lymph node metastases 2, as for evaluable lesions. The response rate was 46.6%, and disease control rate was 86.6%. Hepatic metastatectomy was done in two cases after PR response. There was 1 infusion related reaction case, 1 tumor bleeding and 1 anal fistula as the adverse events. In conclusion, the BV+mFOLFOX6 is one of the effective and feasible regimens for unresectable colorectal cancer.

UI MeSH Term Description Entries
D008297 Male Males
D009944 Organoplatinum Compounds Organic compounds which contain platinum as an integral part of the molecule. Compounds, Organoplatinum
D002955 Leucovorin The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS. Calcium Leucovorin,Citrovorum Factor,Folinic Acid,N(5)-Formyltetrahydrofolate,5-Formyltetrahydrofolate,5-Formyltetrahydropteroylglutamate,Calcium Folinate,Folinic Acid-SF,Leucovorin, (D)-Isomer,Leucovorin, (DL)-Isomer,Leucovorin, (R)-Isomer,Leucovorin, Calcium (1:1) Salt,Leucovorin, Calcium (1:1) Salt, (DL)-Isomer,Leucovorin, Calcium (1:1) Salt, Pentahydrate,Leucovorin, Monosodium Salt,Leukovorin,Leukovorum,Wellcovorin,5 Formyltetrahydrofolate,5 Formyltetrahydropteroylglutamate,Acid, Folinic,Factor, Citrovorum,Folinate, Calcium,Folinic Acid SF,Leucovorin, Calcium,Monosodium Salt Leucovorin
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068258 Bevacizumab An anti-VEGF humanized murine monoclonal antibody. It inhibits VEGF RECEPTORS and helps to prevent PATHOLOGIC ANGIOGENESIS. Avastin,Bevacizumab-awwb,Mvasi,Bevacizumab awwb
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

Rikio Matsumoto, and Toru Kuroda, and Hirofumi Yamada, and Kumi Hasegawa, and Yutaka Mamiya, and Akira Kon
Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei.
April 2020, International journal of clinical oncology,
Rikio Matsumoto, and Toru Kuroda, and Hirofumi Yamada, and Kumi Hasegawa, and Yutaka Mamiya, and Akira Kon
Neurological Toxicity in Metastatic Colorectal Cancer Patients Treated with Modified FOLFOX6 Plus Bevacizumab.
January 2014, Japanese clinical medicine,
Rikio Matsumoto, and Toru Kuroda, and Hirofumi Yamada, and Kumi Hasegawa, and Yutaka Mamiya, and Akira Kon
[Protocol for the administration of modified FOLFOX6 (mFOLFOX6) in patients with unresectable/recurrent colorectal cancer].
November 2013, Gan to kagaku ryoho. Cancer & chemotherapy,
Rikio Matsumoto, and Toru Kuroda, and Hirofumi Yamada, and Kumi Hasegawa, and Yutaka Mamiya, and Akira Kon
Modified Folfox6 as Adjuvant Chemotherapy in Vietnamese Patients With Colorectal Cancer.
January 2019, Cancer control : journal of the Moffitt Cancer Center,
Rikio Matsumoto, and Toru Kuroda, and Hirofumi Yamada, and Kumi Hasegawa, and Yutaka Mamiya, and Akira Kon
[Efficacy of chemotherapy combined with bevacizumab for unresectable advanced or recurrent colorectal cancer].
January 2013, Gan to kagaku ryoho. Cancer & chemotherapy,
Rikio Matsumoto, and Toru Kuroda, and Hirofumi Yamada, and Kumi Hasegawa, and Yutaka Mamiya, and Akira Kon
Reply to comments on "Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei".
March 2021, International journal of clinical oncology,
Rikio Matsumoto, and Toru Kuroda, and Hirofumi Yamada, and Kumi Hasegawa, and Yutaka Mamiya, and Akira Kon
[Elderly patient with recurrent rectal cancer successfully responded to modified FOLFOX6 chemotherapy with bevacizumab--a case report].
June 2010, Gan to kagaku ryoho. Cancer & chemotherapy,
Rikio Matsumoto, and Toru Kuroda, and Hirofumi Yamada, and Kumi Hasegawa, and Yutaka Mamiya, and Akira Kon
[A Case of Recurrent Hyperammonemic Encephalopathy during Adjuvant Chemotherapy(Modified FOLFOX6)for Colorectal Cancer].
November 2018, Gan to kagaku ryoho. Cancer & chemotherapy,
Rikio Matsumoto, and Toru Kuroda, and Hirofumi Yamada, and Kumi Hasegawa, and Yutaka Mamiya, and Akira Kon
Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study.
April 2013, International journal of clinical oncology,
Rikio Matsumoto, and Toru Kuroda, and Hirofumi Yamada, and Kumi Hasegawa, and Yutaka Mamiya, and Akira Kon
Modified FOLFOX6 chemotherapy in patients with metastatic urachal cancer.
January 2013, Chemotherapy,
Copied contents to your clipboard!